Pitt startup rebrands and hires CEO as it seeks funding for final pre-clinical studies for its medical devices to assist in regenerating damaged nerves.
Pitt startup Astria Biosciences continues to rack up milestones as it works to bring the first simple, whole blood-based test to detect the presence and monitor the progression of cerebral aneurysms to market. It’s latest accomplishment: receiving a $275,000 SBIR Phase 1 commercialization grant from the National Science Foundation (NSF). The grant will be applied toward developing a robust data set with a focus on minorities to provide higher test fidelity in high-risk and under-represented patient groups and developing a dynamic rupture risk score that can be used to define novel aneurysm sub-groupings.
From undergrads to PhD candidates, Students Impress Judges with Grasp of Technology and Business Acumen
Company Receives Clearance for Phase I Safety Trial for Treatment of Macular Degeneration. Alan Wells and Cecelia Yates have collaborated on and off for nearly two decades at the University of Pittsburgh developing a class of synthetic proteins that act as switches to turn off the wound healing process. Now, after nearly 7 years of pre-clinical work, the company co-founded and launched from their research has entered a Phase 1 clinical trial with its therapy for the treatment of age-related macular degeneration, also known as wet-AMD.